Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkers

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 412-418

  Schoepfer, Alain M ^a   Vavricka, Stephan ^b   Zahnd Straumann, Nadine ^c   Straumann, Alex ^d   Beglinger, Christoph ^d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Triemlispital Zurich ^*  (Switzerland)

^c Abbott Inc   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Biomarkers; Calprotectin; Inflammatory bowel disease; Monitoring; Mucosal healing

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CYANOCOBALAMIN; IRON;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE SEVERITY; ELECTROPHORESIS; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; MALE; NEUTROPHIL COUNT; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; PRIVATE PRACTICE; QUESTIONNAIRE; SWITZERLAND;

ADULT; AGED; BIOLOGICAL MARKERS; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROENTEROLOGY; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PROGNOSIS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SWITZERLAND;

EID: 84860212388     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.09.008     Document Type: Article

References (33)

1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002, 359:1541-1549.
2. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., Macintosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
3. Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
4. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
5. Harvey R.F., Bradshaw M.J. A simple index of Crohn's disease activity. Lancet 1980, 1:514.
6. Harvey R.F., Bradshaw M.J. Measuring Crohn's disease activity. Lancet 1980, 1:1134-1135.
7. Pineton de Chambrun G., Peyrin-Biroulet L., Lémann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15-29.
8. Arnott I.D., Watts D., Ghosh S. Review Article: Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?. Aliment Pharmacol Ther 2002, 16:857-867.
9. Rutgeerts P., Vermeire S., Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007, 56:453-455.
10. Lichtenstein G.R., Yan S., Bala M., Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91-96.
11. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422. IBSEN Group.
12. Crama-Bohbouth G., Pena A.S., Biemond I., Verspaget H.W., Blok D., Arndt J.W., et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease?. Gut 1989, 30:1236-1240.
13. Sostegni R., Daperno M., Scaglione N., Lavagna A., Rocca R., Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003, 17:11-17.
14. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103:162-169.
15. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Renzulli P., Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009, 15:1851-1858.
16. Terheggen G., Lanyi B., Schanz S., Hoffmann R.M., Böhm S.K., Leifeld L., et al. Safety, feasibility, and tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy 2008, 40:656-663.
17. Mazlam M.Z., Hodgson J.H. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992, 33:773-778.
18. Bitton A., Peppercorn M., Antonioli D., Niles J.L., Shah S., Bousvaros A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
19. Linskens R., van Bodegraven A., Schoorl M., Tuynman H.A., Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci 2001, 46:644-648.
20. Costa F., Mumolo M.G., Ceccarelli L., Bellini M., Romano M.R., Sterpi C., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005, 54:364-368.
21. Johne B., Fagerhol M.K., Lyberg T., Prydz H., Brandtzaeg P., Naess-Andresen C.F., et al. Functional and clinical aspects of the myelomonocytic protein calprotectin. J Clin Pathol Mol Pathol 1997, 50:113-123.
22. Roseth A.G., Aadland E., Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004, 39:1017-1020.
23. Canani R.B., Terrin G., Rapacciuolo L., Miele E., Siani M.C., Puzone C., et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008, 40:547-553.
24. Jones J., Loftus E.V., Panaccione R., Chen L.S., Peterson S., McConnell J., et al. Relationship between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6:1218-1224.
25. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Vavricka S.R., Bruegger L.E, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010, 105:162-169.
26. Sipponen T., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activtiy index and endoscopic findings. Inflamm Bowel Dis 2008, 14:40-46.
27. Burgmann T., Clara I., Graff L., Walker J., Lix L., Rawsthorne P., et al. The Manitoba inflammatory bowel disease cohort study: prolonged symptoms before diagnosis - how much is irritable bowel syndrome?. Clin Gastroenterol Hepatol 2006, 4:614-620.
28. Farrokhyar F., Marshall J.K., Easterbrook B., Irvine E.J. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006, 12:38-46.
29. Keohane J., O'Mahony C., O'Mahony L., O'Mahony S., Quigley E.M., Shanahan F. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?. Am J Gastroenterol 2010, 105:1789-1794.
30. Long M.D., Drossman D.A. Inflammatory bowel disease, irritable bowel syndrome, or what? A challenge to the functional-organic dichotomy. Am J Gastroenterol 2010, 105:1796-1798.
31. Van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135.
32. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
33. Gupta R.B., Harpaz N., Itzkowitz S., Hossain S., Matula S., Kornbluth A., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105.